Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company’s plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.
